LYON, France, Aug. 26, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced its participation in the Seventh International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer, which took place in Los Angeles, August 21-23, 2014. The congress is a joint initiative of the University of Southern California (Los Angeles, USA), Duke University (Durham, USA) and AMC (Amsterdam, Netherlands).
Focal therapy is a technology based paradigm shift in the treatment of localized prostate cancer that is gaining acceptance worldwide. EDAP presented the latest scientific and clinical results of focal-HIFU for prostate cancer with the use of its device, Focal One. Posters, videos and abstracts were presented by Focal One users and outlined the first experience and clinical results with Focal One. The data were well received by delegates at the symposium, as Focal One's unique imaging, treatment and treatment verification technologies position it at the forefront of focal therapies in the modern approach of prostate cancer treatment.
Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "As discussions on best prostate cancer treatment strategies continue among urologists, such international symposiums represent a great opportunity to review the latest in technologies and clinical strategies. Focal One was highlighted multiple times within the scientific program clearly establishing its lead in the field. With our long term worldwide experience in HIFU and the current growing interest in focal therapy, our teams of international experts are already contributing to strategic discussions and decisions on prostate cancer treatment strategies."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2014, the Company introduced a new innovative HIFU device, the Focal One® dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 firstname.lastname@example.org Investors: David Burke The Ruth Group 646-536-7009 email@example.comSource:EDAP TMS SA